Description

This curriculum spans the full bioinformatics workflow for gene fusion analysis, comparable in scope to a multi-phase internal capability program for clinical genomics, covering experimental design, detection, validation, and deployment in production-grade, regulated environments.

Module 1: Foundations of Gene Fusion Biology and Clinical Relevance

Select appropriate reference genomes (e.g., GRCh38 vs. GRCh37) based on alignment compatibility with fusion detection tools and availability of clinically annotated fusion databases.
Evaluate tissue-specific expression patterns to distinguish driver fusions from passenger events in oncogenic contexts.
Assess the impact of fusion breakpoints on protein domains using domain databases like Pfam or InterPro to predict functional consequences.
Integrate knowledge of known oncogenic fusions (e.g., BCR-ABL1, EML4-ALK) into assay design for targeted sequencing panels.
Determine whether to include intronic regions in sequencing capture design based on known fusion breakpoint distribution in target genes.
Map fusion events to clinical actionability using resources like OncoKB or CGI to prioritize variants for reporting.
Establish thresholds for fusion expression levels below which biological relevance is questionable in RNA-seq data.
Classify fusions by mechanism (e.g., translocation, read-through, retrotransposition) to inform downstream validation strategies.

Module 2: Experimental Design and Sequencing Methodologies

Choose between whole-transcriptome RNA-seq and targeted panel sequencing based on sample input, cost constraints, and required sensitivity for low-expression fusions.
Optimize RNA integrity number (RIN) thresholds for sample inclusion, particularly in FFPE-derived samples with degraded RNA.
Decide on stranded vs. non-stranded library preparation based on ability to resolve antisense transcription and fusion orientation.
Set read length and depth requirements (e.g., ≥50M paired-end 150bp reads) to ensure sufficient spanning and split-read support for fusion detection.
Implement unique molecular identifiers (UMIs) in library prep to mitigate PCR duplication artifacts in low-input samples.
Select between poly-A selection and rRNA depletion based on sample type and potential for non-polyadenylated fusion transcripts.
Design hybridization probes for targeted panels to maximize coverage of known intronic breakpoint hotspots in fusion-prone genes.
Include positive control cell lines (e.g., K-562 for BCR-ABL1) in sequencing runs to monitor assay performance.

Module 3: Preprocessing and Quality Control of NGS Data

Apply adapter trimming and quality filtering using tools like Trimmomatic or fastp with parameters tuned for RNA-seq data.
Assess sequencing saturation and duplication rates to determine if UMI-based deduplication is necessary.
Monitor batch effects across sequencing runs using PCA on gene expression profiles before fusion calling.
Exclude samples with high ribosomal RNA content post-rRNA depletion from downstream analysis.
Validate strand specificity using RSeQC to confirm library preparation fidelity.
Correct for GC bias in coverage, particularly in regions flanking fusion breakpoints, using normalization methods.
Align reads to both genomic and transcriptomic references to support split-read and discordant-pair detection.
Flag samples with low mappability due to high sequence divergence or contamination using Kraken or FastQ Screen.

Module 4: Fusion Detection Algorithms and Tool Integration

Run multiple fusion callers (e.g., STAR-Fusion, Arriba, FusionCatcher) in parallel to increase sensitivity and reduce false negatives.
Configure STAR aligner with outFilterMultimapScoreRange and alignSJoverhangMin to optimize splice junction detection for fusion calling.
Adjust minimum supporting read thresholds (e.g., ≥2 spanning reads, ≥1 split read) based on sequencing depth and background noise.
Filter fusions involving pseudogenes or paralogs using sequence homology databases to reduce false positives.
Integrate results from DNA-based structural variant callers (e.g., Manta) to validate RNA-observed fusions at the genomic level.
Exclude fusions with alignment artifacts caused by homopolymer regions or low-complexity sequences.
Use annotation databases (e.g., COSMIC, ChimerDB) to prioritize known pathogenic fusions during result filtering.
Implement a tiered classification system (Tier I–IV) for fusions based on evidence level and clinical relevance.

Module 5: Annotation and Functional Interpretation of Fusions

Map fusion breakpoints to exon-intron boundaries to predict in-frame vs. out-of-frame transcripts using RefSeq or Ensembl annotations.
Determine whether the 5’ and 3’ partner genes retain functional domains post-fusion using protein domain databases.
Assess promoter swapping potential by analyzing expression levels of the 5’ partner gene in normal tissues.
Annotate kinase domain retention in fusion proteins to evaluate druggability (e.g., in ALK, ROS1, NTRK fusions).
Use gene ontology and pathway analysis (e.g., Reactome, KEGG) to infer disrupted biological processes.
Integrate expression data to determine if the fusion transcript is expressed at biologically relevant levels.
Flag fusions involving tumor suppressor genes where truncation may lead to loss of function.
Compare fusion isoforms across databases to identify novel splice variants with potential functional impact.

Module 6: Validation and Clinical Reporting

Select orthogonal validation method (RT-PCR, Sanger sequencing, or FISH) based on fusion architecture and available sample material.
Design PCR primers spanning the fusion junction with Tm balancing and specificity checks against reference genome.
Establish minimum validation thresholds (e.g., ≥50% concordance across replicates) for reporting in clinical contexts.
Document bioinformatics pipeline versioning, parameters, and reference databases used for audit and reproducibility.
Define reporting thresholds for variant allele frequency and read support in clinical-grade fusion reports.
Include confidence levels (e.g., confirmed, probable, artifact) in reports based on supporting evidence tiers.
Redact incidental findings unrelated to the clinical indication unless they meet ACMG secondary findings criteria.
Implement structured reporting using standardized vocabularies (e.g., HGVS nomenclature, HUGO gene symbols).

Module 7: Data Integration and Multi-Omics Context

Correlate fusion status with copy number alterations (e.g., MYC amplification in fusion-positive cancers) using joint analysis.
Assess mutational burden and co-occurring SNVs/indels to determine if the fusion is part of a broader mutational signature.
Integrate methylation data to evaluate epigenetic silencing of the non-fused allele in tumor suppressor gene fusions.
Overlay fusion data with protein expression (e.g., RPPA or IHC) to confirm translation of fusion transcripts.
Use single-cell RNA-seq to resolve fusion heterogeneity within tumor subclones.
Compare fusion expression across tumor and normal compartments in spatial transcriptomics datasets.
Link fusion events to immune microenvironment profiles (e.g., T-cell infiltration) for immunotherapy relevance.
Aggregate fusion data with clinical outcomes in retrospective cohorts to assess prognostic significance.

Module 8: Governance, Reproducibility, and Regulatory Compliance

Implement containerization (e.g., Docker/Singularity) to ensure pipeline portability and version control.
Adopt workflow languages (e.g., Nextflow, Snakemake) to standardize and document analysis pipelines.
Establish audit trails for all data processing steps using metadata tracking systems (e.g., LIMS).
Define data retention policies for raw and processed files in compliance with CLIA or HIPAA requirements.
Conduct periodic bioinformatics pipeline validation using reference datasets (e.g., SEQC-2) to maintain accuracy.
Restrict access to sensitive genomic data using role-based access control and encryption at rest.
Document deviations from standard operating procedures during troubleshooting for regulatory review.
Participate in external quality assessment (EQA) programs for molecular pathology to benchmark fusion detection performance.

Module 9: Scalability and Deployment in Production Environments

Design cloud-based analysis pipelines with autoscaling to handle variable sequencing batch loads.
Optimize I/O operations for large BAM files using parallel processing and distributed file systems.
Implement automated failure recovery for long-running fusion detection workflows.
Cache frequently accessed reference data (e.g., genome indices, annotation files) to reduce latency.
Monitor compute costs per sample and optimize resource allocation (CPU, memory) per tool.
Develop APIs to integrate fusion calling results into laboratory information systems (LIS).
Enable real-time status tracking for samples moving through the analysis pipeline.
Support multi-institutional data sharing using federated analysis frameworks while preserving data locality.